26 Results for "

complement C5 inhibitor

" in MedChemExpress (MCE) Product Catalog:
Products (26)

26 Results for "complement C5 inhibitor" in MCE Product Catalog:

Cat. No.: HY-153098A
Purity:  94.13%
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

ARC186 (sodium) is an unconjugated 40KDa PEG aptamer with a sequence identical to HY-147080 Avacincaptad pegol (ARC1905) sodium. ARC1905 is highly potent complement inhibitors that function by blocking the convertase-catalyzed activation of C5.
loading...
    loading...
Cat. No.: HY-153785
Purity:  92.50%
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

NH2-C6-ARC186 sodium is a modified ARC186 (HY-153098) with NH2-C6 that can be coupled to other peptides or molecules. ARC186 is a aptamer and a highly potent complement inhibitor that function by blocking the convertase-catalyzed activation of C5 .
loading...
    loading...
Cat. No.: HY-P5509
CAS No.: 230968-98-6
Target:  

Inhibitory Antibodies

Research Areas:  

Others

C5aR1 antagonist peptide is a biological active peptide. (This linear peptide is derived from the C-terminus of the chemokine, complement fragment 5 anaphylatoxin (C5a). This peptide functions to inhibit C5a binding and function at human and rat C5a receptors. C5a is crucial to triggering cellular immune responses and its overexpression is involved in arthritis, Alzheimer’s disease, cystic fibrosis, systemic lupus erythematosus, and other immunoinflammatory diseases.)
loading...
    loading...
Cat. No.: HY-P990955
CAS No.: 2839652-75-2
Synonyms: ADX-097

Target:  

CD3 Complement System

Research Areas:  

Inflammation/Immunology

Ebribafusp alfa (ADX-097) comprising a humanized anti-C3d monoclonal antibody linked to two moieties of the first five consensus repeats of factor H (fH1-5). Ebribafusp alfa binds C3d and related fragments, catalyzes AP convertase dissociation, acts as a factor I co-factor for C3b cleavage, and delivers fH1-5 moieties to C3d-deposited tissues for local complement inhibition without systemic blockade. Ebribafusp alfa reduces glomerular C3 deposition, proteinuria, urine albumin-creatinine ratios, and urine soluble C5b-9 levels, preserves podocyte foot-process architecture, inhibits skin complement activation, and localizes to UVB-damaged primate skin. Ebribafusp alfa can be used for the research of membranous nephropathy, bullous pemphigoid, discoid lupus erythematosus, C3 glomerulopathy, IgA nephropathy, and lupus nephritis .
loading...
    loading...
Cat. No.: HY-P991022
CAS No.: 2842046-67-5
Synonyms: NM8074

Target:  

Complement System

Research Areas:  

Endocrinology

Ruxoprubart (NM8074) is an inhibitor of complement factor B (Bb subunit). Ruxoprubart selectively binds to active Bb to inhibit the alternative complement pathway without affecting the classical complement pathway. By blocking the activities of AP C3 and C5 convertases, Ruxoprubart effectively inhibits red blood cell hemolysis and reduces C3b deposition, thereby preventing intravascular and extravascular hemolysis. Ruxoprubart can be used in research related to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and IgA nephropathy .
loading...
    loading...
Cat. No.: HY-17627S1
CAS No.: 2316781-85-6
Synonyms: CCX168-d4
Avacopan-d4 (CCX168-d4) is the deuterium labeled Avacopan (HY-17627). Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
loading...
    loading...